About the ISCBH

Mission and vision

The International Society for Children’s Bone Health is a scientific society dedicated to achieving the best bone health in every child across the globe through research, education, collaboration and advocacy. Our aims are:

  • To advance scientific knowledge through the organisation of conferences, webinars, workshops and other events
  • To promote basic and clinical research on topics relating to bone health in children
  • To educate through the organisation of training courses and other educational activities
  • To act as an umbrella for a multi-disciplinary community to promote exchange of information and collaboration
  • To raise public awareness and to act as an authoritative body on topics relating to bone health in children


The ISCBH was registered as a Society in Austria on 14 November 2022

The governing body of the ISCBH is the Council & the Executive Committee, comprising the President, Treasurer, Secretary, and Trustees.

All membership is subject to approval by the ISCBH Secretary

Committees & People

Executive Committee


Frank Rauch

Frank Rauch

Montreal, Canada


Adalbert Raimann

Vienna, Austria


Ciara McDonnell

Dublin, Ireland​

Steering Committee

Antonella Forlino

Antonella Forlino

Pavia, Italy

Wolfgang Högler

Linz, Austria

Alex Ireland

Manchester, UK

Outi Mäkitie

Helsinki, Finland

Craig Munns

Craig Munns

Brisbane, Australia

Leanne Ward

Leanne Ward

Ottowa, Canada

Alison Boyce

Alison Boyce

Bethesda, USA

Marie-Eve Robinson

Ottowa, Canada


Amanda Helm

Executive director

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.